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Abstract
Fluorogenic assays have many potential advantages over traditional clot-based and
chromogenic assays such as the absence of interference from a range of factor deficiencies as
well as offering the possibility of assays in platelet rich plasma or whole blood. A fluorogenic
anti-factor Xa (anti-FXa) assay has been developed for the determination of heparin-like
anticoagulants including unfractionated heparin (UFH), low-molecular weight heparins
(LMWHs), namely enoxaparin and tinzaparin, and the synthetic heparinoid danaparoid, in
commercial human pooled plasma. The assay was based on the complexation of heparinspiked plasmas with exogenous FXa at a concentration of 4 nM in the presence of 0.9 µM of
the fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4methylcoumarin acetate (Pefafluor FXa). Pooled plasma samples were spiked with
concentrations of anticoagulants in the range 0 to 1.6 U/ml. The assay was capable of the
measurement of UFH and danaparoid in the range 0-1 U/ml, and enoxaparin and tinzaparin in
the range 0-0.8 U/ml and 0-0.6 U/ml, respectively. Assay percentage coefficients of variation
were typically below 7 %.
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1. Introduction
Antithrombotic drugs are routinely used for a wide range of clinical indications,
including the prevention and treatment of venous thromboembolism (VTE) and the acute
management of ischaemic heart disease [1, 2]. Unfractionated heparin (UFH) constitutes the
most widely used parenteral antithrombotic therapy [3, 4], and consists of a heterogeneous
mixture of negatively-charged glycosaminoglycans derived from either bovine lung, or
porcine intestine. UFH exerts its anticoagulant effect primarily through binding to plasma
antithrombin (AT) [5]. This binding causes a conformational change in antithrombin, which
markedly enhances the ability of antithrombin to specifically inhibit procoagulant factors Xa
(FXa) and thrombin (IIa) [1].
Low molecular weight heparins (LMWHs) are synthesised by chemical or enzymatic
depolymerisation of heterogeneous UFH glycosaminoglycan chains [1, 6]. LMWHs
demonstrate better bioavailability, have significantly longer half-lives compared to UFH [1],
and are also associated with reduced incidence of significant complications [7].
Consequently, UFH has been replaced by LMWH as the treatment of choice for many
indications. Although the LMWHs share many pharmacodynamic properties, commercial
products differ significantly with respect to final molecular weights (4000-7000 Da) [4].
Although the LMWHs all bind to AT, they demonstrate different abilities to enhance
inactivation of FXa and/or thrombin (anti-FXa:anti-FIIa ratios ranging from 2:1 to 4:1) [8].
Danaparoid is prepared from bovine and porcine mucosa, and is classed as a low molecular
weight heparinoid which has an anti-FXa:anti-IIa ratio of ≥22:1 [9].
Despite its widespread use, it is well recognized that UFH has a relatively narrow
therapeutic window [1]. Consequently, laboratory monitoring and dose-titration of UFH
therapy is standard clinical practice. In contrast, because of more predictable pharmacokinetic
profiles, LMWH therapy typically requires less laboratory monitoring. A number of different
3

laboratory assays have been used to enable adjustment of heparin doses. Most commonly
used are clot-based assays in the form of the activated partial thromboplastin time (APTT)
[10] and the activated clotting time (ACT) [11]. Nevertheless, it is well established that these
assays have a number of important limitations. First, since the APTT is a standard end-point
clotting time assay, it can be influenced by many other coagulation variables. For example,
the APTT will be prolonged by inherited or acquired coagulation factor deficiencies
(including factors XII, XI, X, IX, VIII, V, and II) [8, 12]. Second, more than 300 different
laboratory tests are in clinical use to measure the APTT. Previous reports have clearly shown
that varying combinations of different commercial reagents and coagulometer machines can
result in marked inter-laboratory variability in responsiveness to therapeutic UFH
concentrations [13, 14]. Similarly, although the ACT is widely used to monitor heparin
reversal in patients during cardiac surgery, it is also associated with important limitations
[15].
Since the APTT is generally insensitive to LMWH, plasma anti-FXa activity
monitoring is established as the assay of choice for those patients who require monitoring. In
addition, the anti-FXa assay can also be used to monitor UFH levels. Moreover, since the
anti-FXa assay generally involves a chromogenic end-point, use of this assay to monitor UFH
levels is attractive in that it is not affected by many of the other biologic variable that can
interfere with clot-based end-points. While chromogenic assays confer many advantages over
standard clot-based assays, there are some drawbacks. The use of chromogenic substrates
requires measuring optical density, which renders whole blood and platelet rich plasma
samples problematic for colorimetric measurements [16]. Fibrinogen clotting results in
turbidity of plasma samples which interferes negatively with absorbance readings [16-18].
Also the lack of a standard anti-FXa chromogenic assay gives rise to significant intervariability between commercially available assays [13, 19].
4

The potential advantages of fluorogenic assays over chromogenic assays include the
ability to use a range of sample types such as platelet poor (PPP), platelet rich (PRP) and
whole blood samples, as fluorescence is not as influenced by the opacity of the sample as
absorbance [18]. Although fluorogenic assays to assess thrombin generation have been
developed, there is accumulating evidence that FXa may represent a better target as it
occupies a critical junction in the coagulation cascade [20]. In this study, we have sought to
develop a novel plate-based fluorogenic anti-FXa assay that is sensitive to pharmacological
concentrations of UFH, LMWHs, and danaparoid.
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2. Materials and methods
2.1. Reagents
Water (ACS reagent), HEPES (minimum 99.5% titration) and sodium citrate tribasic
dehydrate (ACS reagent, 99.0%) were all from Sigma-Aldrich (Ireland). Filtered HEPES and
sodium citrate solutions had concentrations of 10 mM (pH 7.4) and 0.1 M (pH 5.5),
respectively. A 100 mM filtered stock solution of CaCl2 was prepared from a 1 M CaCl2
solution (Fluka BioChemika, Switzerland). The fluorogenic substrate methylsulfonyl-Dcyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa) was
purchased from Pentapharm (Basel, Switzerland). It was reconstituted in 1 ml of water
having a final concentration of 10 mM, aliquoted and stored at -20°C until further use.
Dilutions from 10 mM stock solutions down to 10 µM were freshly prepared with water
when needed. Subsequent dilutions were prepared in 10 mM HEPES. Tubes were covered
with aluminum foil to protect from exposure to light. Purified human Factor Xa (FXa) was
obtained from HYPHEN BioMed (Neuville-Sur-Oise, France). Tinzaparin (Innohep®) was
obtained from LEO Pharma (Ballerup, Denmark). UFH, enoxaparin (Clexane®) and
danaparoid (Orgaran®) were from Sigma-Aldrich (St Louis, MO), Sanofi-Aventis (Paris,
France) and Schering-Plough (Kenilworth, NJ), respectively. Human pooled plasma was
purchased from Helena Biosciences Europe (Tyne and Wear, UK). Lyophilised plasma was
reconstituted in 1 ml of water and left to stabilize for at least 20 min at room temperature
prior to use.
2.2. Apparatus and software
Fluorescence intensities were measured in a microplate reader (Spectrophotometer Infinite
M200, Tecan Group Ltd., Switzerland) equipped with a UV Xenon flashlamp. Flat, blackbottom 96-well polystyrol microplates (Nunc™ FluoroNunc™ Microplates, Roskilde,
Denmark) were used.
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2.3. Fluorogenic anti-FXa assay
Measurements were carried out in reconstituted citrated human pooled plasma without
the addition of exogenous AT. FXa and Pefafluor FXa were titrated within the range of 0.110 nM and 0.1-100 µM (Km = 220 µM), respectively. Each well contained 6.25 µl of 100 mM
CaCl2, 43.75 µl of pooled plasma, and 50 µl of FXa (0.1-10 nM). The reaction was started by
adding 50 µl of Pefafluor FXa fluorogenic substrate (0.1-100 µM). Samples within wells
were mixed with the aid of orbital shaking at 37°C for 30 s. Immediately after shaking,
fluorescence measurements were recorded at 37°C for 60 min, at 20 µs intervals.
Fluorescence excitation was at 342 nm and emission was monitored at 440 nm,
corresponding to the excitation/emission wavelengths of the 7-amino-4-methylcoumarin
(AMC) fluorophore. All the measurements were carried out in triplicate. Following
optimization of assay conditions, pooled commercial plasma samples were spiked with
pharmacologically relevant concentrations (0–1.6 U/ml) of therapeutic anticoagulants
including UFH, enoxaparin, tinzaparin and danaparoid. In all experiments, reaction progress
curves were obtained and analyzed in SigmaPlot 8.0. The reaction rate, which is defined as
the change in fluorescence divided by the change in time (i.e., dF/dt), was measured as the
linear portion of the fluorescence response profile and plotted versus all different
anticoagulant concentrations.
2.4. Statistical Analysis
Inter- and intra-assay differences between anticoagulant concentrations were compared using
one-way analysis of variance (ANOVA), with subsequent post-hoc analysis performed
(Scheffe test) if significance was observed. A result of (p<0.05) was considered statistically
significant. The statistical package SPSS 15.0 was used for data processing and analysis.
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3. Results
3.1. Assay optimization
In standard anti-FXa assays, excess FXa added to heparinized plasma is inhibited by
the heparin-AT complex, and residual FXa activity is assessed using a chromogenic substrate
[19, 21]. Our assay measures the rate of AMC fluorophore released by FXa substrate
cleavage, which is inversely dependent upon plasma heparin(oid) concentration. To establish
optimal assay concentrations, Pefafluor FXa fluorogenic substrate and FXa were titrated over
a range of concentrations. Pefafluor FXa substrate concentration was evaluated within the
range of 0.1 µM (0.45 x 10-3 times Km) to 100 µM (0.45 times Km) with FXa in excess of
physiological concentrations (150 pM) [22] at a concentration of 1 nM. Pefafluor FXa
concentrations were chosen on the basis of working below and around the Km value to allow
differentiation in reaction rates at different anticoagulant concentrations, as the difference in
reaction rates at substrate concentrations larger than the Km is almost negligible. An example
of the fluorogenic assay FXa/substrate titration (0.8 µM substrate and 0.1, 1 and 10 nM FXa
concentrations) can be seen in Fig. 1. The optimized assay is capable of differentiating the
concentration of UFH in commercial human pooled plasma from 0 to 1 U/ml, at a final assay
concentration of 4 nM FXa and 0.9 µM Pefafluor FXa.
(Figure 1)
3.2. Evaluation of the anti-FXa fluorogenic assay for the quantitative determination of
anticoagulant dose-response and assay variability
Four heparin drugs were tested using the optimized fluorogenic anti-FXa assay in
commercial human pooled plasma. The reaction progress curves were similar for all four
drugs in that, as anticoagulant concentration increased, lag times were extended and reaction
rates were reduced. This is illustrated in Fig. 2 (inset) which shows the fluorescence profiles
of the anti-FXa assay response to UFH. For each type of anticoagulant, the reaction curves
8

reached a plateau at approximately the same level (48,000-53,000 AU) independent of
anticoagulant concentration. This upper response limit was dictated by the substrate (and thus
product) concentration and the upper detection limit of the instrument.
(Figure 2)
The dose-response profile for the assay in UFH was calculated using the linear
regions of the fluorescence responses. It can be observed that the assay was capable of the
differentiation of UFH concentrations from 0.2 to 1.6 U/ml at intervals of 0.2 U/ml. The
overall response profile was non-linear. It has previously been reported that non-linearity is
observed with wide-ranging concentrations of heparin [23] and that the half-life and intensity
of the effects of heparin rise disproportionately with increasing heparin dose [4]. Highest
assay sensitivity can be observed at lower heparin concentrations (0-0.6 U/ml) but at the
upper range (0.6-1.6 U/ml) the sensitivity of the assay decreased significantly. Response
slopes to UFH concentrations at 0.2 U/ml intervals were statistically different from one
another (p<0.001) up to 1 U/ml UFH except for UFH concentrations of 0.6 U/ml and 0.8
U/ml between which there was no statistical difference (p=0.441).
The anti-FXa assay was tested further on a range of anticoagulant drugs, namely
tinzaparin, enoxaparin and danaparoid. The fluorescence response profiles of the fluorogenic
anti-FXa assay to tinzaparin and the associated dose-response curve can be seen in Fig. 3.
Typically, the responses reached a plateau of around 50,000 – 55,000 AU and lag times
increased while the slopes of the linear response region decreased with increasing
concentration. In nearly all instances there were statistically significant differences between
the slopes of the adjacent drug concentrations (p<0.001). The resulting dose-response curve
was non-linear, with higher sensitivity in the lower tinzaparin range (0.2-0.6 U/ml). At higher
concentrations of the anticoagulant, assay sensitivity again decreased, which was similar to
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that observed for UFH. However, the highest dose tested (1.6 U/ml) could still be
distinguished from the next concentration of 1.4 U/ml (p<0.001). LMWHs have been
reported as giving a more predictable dose-response than UFH due to better bioavailability at
low doses.
(Figure 3)
The effect of enoxaparin was also evaluated using the fluorogenic anti-FXa assay
(Fig. 4). Fluorescence response curves showed comparable characteristics to UFH and
tinzaparin and again reached a plateau around 50,000 AU. However, the dose-response curve
shows that, although the anti-FXa assay had good sensitivity to enoxaparin between 0 and 0.4
U/ml and retained moderate sensitivity up to 0.8 U/ml, at concentrations greater than 1.0
U/ml the assay showed a significant loss in sensitivity (p>0.05).
(Figure 4)
Fig. 5 shows the fluorescence responses from the anti-FXa assay in the presence of
danaparoid. Again, similar to earlier results, the fluorescence responses reached a plateau
between 45,000-50,000 AU. However, the lag times were more prolonged in the presence of
danaparoid than in the presence of UFH. For example, at 0.8 U/ml danaparoid, the lag time
ended at 2000 s compared to UFH which ended at 500 s. The slopes in the presence of
danaparoid were also much lower than for UFH. This is likely due to the more complete
inhibition of FXa by danaparoid as a result of its high anti-FXa:anti-FIIa activity ratio of
≥22:1 [9]. At 1.2 U/ml the reproducibility also became a significant issue with a %CV of
21%. Above this, it was not possible to calculate meaningful slopes. This assay was found to
be statistically sensitive to danaparoid up to concentrations of 1 U/ml (p<0.001).
(Figure 5)
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Although there was a significant difference between activity at 0 and 0.2 U/ml, there
was a near linear response of anti-FXa activity with danaparoid at concentrations of 0.2-1
U/ml (R2=0.9891) which was not seen with UFH, tinzaparin or enoxaparin indicating a more
predictable dose-response relationship. While danaparoid has little effect on standard clotting
tests [4] it can be monitored with the anti-FXa fluorogenic assay developed in this study quite
reliably.
Also critical to assay performance is the relative standard deviation or percentage
coefficient of variation (%CV). Table 1 summarizes the analytical errors associated with each
of the slope measurements, namely the standard deviation and the percentage coefficient of
variation for each anticoagulant drug in the anti-FXa assay. CV values for all drugs tested
were <7% for the plate-based assay (except for a single point at 1.2 U/ml danaparoid) which
are in line with commercially available assays [24, 25] and the WHO Expert Committee on
Biological Standardization reports.
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Table 1.
Percentage coefficient of variation (%CV) and standard deviation (SD) for all anticoagulants
tested (n=3).
Concentration UFH

Tinzaparin

Enoxaparin

Danaparoid

(U/ml)
SD

%CV

SD

%CV

SD

%CV

SD

%CV

0

7.29

6.26

5.03

3.16

1.94

1.73

1.3

0.96

0.2

1.29

1.23

1.43

1.75

1.03

1.52

2.55

4.56

0.4

2.42

3.36

2.68

4.00

0.30

0.73

1.64

3.35

0.6

0.17

0.33

1.70

4.13

0.56

0.50

2.34

6.27

0.8

2.13

4.61

2.48

6.55

1.62

5.28

1.02

4.13

1.0

1.87

4.54

0.42

1.39

10.5

3.83

0.54

3.01

1.2

0.42

1.4

1.40

5.25

0.57

2.12

4.27

20.95

1.4

1.25

4.59

0.71

5.14

0.18

0.74

-

-

1.6

0.83

4.19

0.44

4.13

1.11

5.52

-

-

3.3. Comparison of responses of the anti-FXa assay to different drugs
The inter-assay variability between drugs was also assessed. While the general trend
for each drug was similar (Fig. 6), specific differences were observed in the response of each
drug. An indication of the inter-assay variation is given by the results for the 0 U/ml
measurements for the four assays. As can be seen in Fig. 6, this value varied from approx.
115 AU/s to 160 AU/s. This variation could be due to variations in antithrombin activity
levels in the control plasma, variations in exogenous Xa activity levels, or other experimental
variables such as time and temperature. As a result, the inter-assay variability was 16%.
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(Figure 6)
Statistical analysis of the raw data indicated that concentrations of 0.2, 0.4, and 0.8
U/ml, for all four drugs tested were significantly different from one another (p<0.001) with
the exception of tinzaparin and UFH at 0.4 U/ml (p=0.78). At 0.6 U/ml and 1 U/ml the
Levene’s test was p=0.020 and p=0.032, respectively. Hence, there were significant
differences in the variances and therefore one-way ANOVA could not be applied. At
concentrations of 1.2, 1.4, and 1.6 U/ml, statistical analysis showed significant differences
between UFH, enoxaparin, and tinzaparin. Danaparoid data was not recorded within this
range.
To eliminate differences due to inter-assay variation, ratios of the dose-responses
were made against those at 0 U/ml heparin. Statistical analysis of this normalized data
showed specific differences from the raw data. UFH was seen to be distinctive from the
LMWHs and danaparoid where it showed comparatively less decrease in assay activity for
comparable doses, particularly at lower concentrations. Concentrations of 0.2, 0.8, 1, 1.4 and
1.6 U/ml for all four drugs tested were significantly different (p<0.001). However at 0.8
U/ml, tinzaparin and enoxaparin were not significantly different (p=0.069). Also, UFH and
enoxaparin were not significantly different at 1.4 U/ml (p=0.064) and 1.6 U/ml (p=0.433). At
concentrations of 0.4 U/ml (p=0.043), 0.6 U/ml (p=0.011) and 1.2 U/ml (p=0.004) significant
differences were identified in the variances, so one-way ANOVA could not be applied.
The responses of all four drugs to the anti-FXa fluorogenic assay can be further
compared using the reaction rates (slopes) of the normalized data. UFH at 0.2, 0.4, 0.8, 1.2,
1.4 and 1.6 U/ml returned higher reaction rates than both LMWHs and danaparoid.
Enoxaparin reaction rates were higher than tinzaparin reaction rates at 0.2, 0.8, 1.4 and 1.6
U/ml but at all other concentrations the reaction rates were the same. Danaparoid returned the
lowest reaction rates. This pattern could relate to the molecular weights of each drug with
13

UFH at 11,393 Da, tinzaparin at 5,866 Da and enoxaparin at 4,371 Da and danaparoid at a
similar molecular weight to LMWHs. At higher molecular weights, greater reaction rates
were calculated indicating greater sensitivity of the assay to that particular drug. In addition a
trend can be observed between reaction rates and anti-FXa:anti-IIa ratios which also
correlates with the pattern observed with molecular weight, e.g.
UFH>tinzaparin>enoxaparin>danaparoid : 1:1>1.9:1>2.7:1≥22:1. A high anti-FXa:anti-FIIa
ratio and low molecular weight translates into a lower reaction rate value.
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4. Discussion
Injectable drugs such as UFH, LMWHs and associated synthetic heparinoids are
widely used and extremely efficacious anticoagulant treatments. However, UFH needs
careful monitoring as it suffers significantly from a narrow therapeutic window and the
subsequent harmful implications of clotting or bleeding. As already discussed, monitoring of
UFH has long relied on clot-based assays (APTT and ACT) which have significant
limitations. Furthermore, although LMWHs require less laboratory monitoring due to their
predictable pharmacokinetics, monitoring is recommended in populations where
pharmacokinetic parameters are altered, including obesity, renal insufficiency, pregnancy, in
underweight patients, elderly patients and children [7, 26].
The aim of this study was to develop a novel, reproducible, and sensitive assay using
fluorescence to quantify heparin-like drugs in human pooled plasma. Consequently, we
measured the effect of four anticoagulants, UFH, enoxaparin, tinzaparin and danaparoid on
the fluorogenic anti-FXa assay at anticoagulant concentrations of 0-1.6 U/ml. The intra-assay
variability and sensitivity limit was established for each of these four drugs. In addition we
investigated the inter-variability of the assay for all drugs, so the assay for UFH was
compared with the assay for LMWHs and danaparoid. SPSS statistical analysis proved that
there were significant differences in assay sensitivity between drugs.
In the study presented here the anti-FXa assay for UFH was statistically differentiated
at intervals of 0.2 U/ml up to 1 U/ml and showed excellent reproducibility with CVs below
7%. The anti-FXa assay was also statistically sensitive up to 0.6 U/ml and 0.8 U/ml for
tinzaparin and enoxaparin, respectively. Assay reproducibility for both LMWHs was
excellent with CVs of 0.5-7%. The anti-FXa:anti-FIIa ratios for enoxaparin and tinzaparin are
2.7:1 and 1.9:1, both exerting a larger inhibitory effect on FXa than thrombin. As has already
been stated, LMWHs have less of an effect on ACT and APTT than UFH [6], supporting the
15

theory that prolongation of these tests is dependent upon inhibition of thrombin rather than
FXa, highlighting the need for an anti-FXa activity test. The use of a single calibration curve
for monitoring LMWHs in children has also been suggested [27]. Strong linearity was
observed for tinzaparin and enoxaparin calibration curves, with a slight bias towards lower
anti-FXa activity with tinzaparin. However, the difference was not significant. With the
present fluorogenic anti-FXa assay, the reaction rates for enoxaparin were marginally higher
than for tinzaparin, but the differences were not statistically significant as previously reported
in the literature [27].
The use of a point of care chromogenic anti-FXa assay for monitoring enoxaparin in
patients who have undergone percutaneous coronary intervention (PCI) has been described
[28]. The chromogenic ENOX assay described can detect anti-FXa levels of 0.63-1.34 U/ml.
However, at lower ranges of anti-FXa activity, the sensitivity of the assay decreases. An
analytical range of 0.5-1 U/ml is appropriate for PCI [29, 30] and the fluorogenic assay
presented here covers this therapeutic range as well as low dose enoxaparin (0.2-0.8 U/ml).
Danaparoid has the greatest ratio of anti-FXa:anti-FIIa (≥22:1) amongst the
anticoagulants evaluated and inhibits FXa to a much greater extent than FIIa [4]. The antiFXa assay is considered to be the only adequate assay for monitoring danaparoid. In the
present study, it was established that the fluorogenic anti-FXa assay was capable of detection
and discrimination of danaparoid up to 1 U/ml where it demonstrated good reproducibility
with CVs of less than 7%, in addition to good linearity between 0.2 and 1 U/ml. Danaparoid
cannot be measured using PT, APTT or thrombin clotting time. However, there is a
requirement to monitor it in patients with elevated levels of creatinine in serum [4]. A study
compared the APTT, ACT and anti-FXa assays for monitoring danaparoid during
cardiovascular operations [31]. In spiked samples, APTT and ACT were prolonged in the
presence of increasing concentrations of danaparoid. However, in patient samples, both
16

assays were insensitive to significant changes in danaparoid levels. The present assay needs
to undergo evaluation in patient samples before its usefulness can be fully determined.
In conclusion, a novel fluorogenic anti-FXa assay has been developed which is
capable of measuring the impact on the anti-FXa activity of therapeutic concentrations of
several heparin-like anticoagulants, namely UFH, tinzaparin, enoxaparin and danaparoid. The
assay used 4 nM exogenous FXa and 0.9 µM Pefafluor FXa substrate and was performed in
commercial human pooled plasmas. This single assay configuration resulted in detection
ranges of 0 to 1 U/ml for UFH, 0 to 0.6 U/ml tinzaparin, 0 to 0.8 U/ml enoxaparin, and 0 to 1
U/ml for danaparoid with discrimination between doses of 0.2 U/ml in nearly all cases and
typical CVs below 7%.
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